Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Cancers
•
Endometrial Cancer
Would you consider the addition of trabectedin to adjuvant doxorubicin in a patient with IVB leiomyosarcoma with completely resected disease (hysterectomy and thigh mass with negative margins)?
Related Questions
How do you classify extensive LVSI in endometrial cancer?
Given the negative results of GOG-0238 but the positive results of the RUBY trial, how do you manage isolated vaginal cuff recurrence of endometrial cancer?
How do you manage a patient with widely metastatic serous endometrial cancer whose disease is stable after completion of 6 cycles of chemotherapy + immunotherapy?
In light of new NCCN guidelines that state combination chemotherapy + pelvic RT should be reserved for endometrial cancer of at least stage IIIB, will you recommend EBRT in addition to chemotherapy for stage IIIA endometrial cancers?
Would you add olaparib to maintenance immunotherapy for a patient with recurrent MMR-proficient, HER2-negative serous endometrial carcinoma?
When do you consider adjuvant chemotherapy and/or RT for stage I-III high-grade uterine sarcomas s/p resection?
Would you consider the addition of trastuzumab to carboplatin/paclitaxel for an advanced uterine carcinosarcoma that stains HER2 IHC 3+ in the carcinomatous components but IHC 0 in the sarcomatous regions?
How would you manage a patient with FIGO 2018 IA G3 endometrioid adenocarcinoma with substantial LVSI, and was N- with adequate nodal staging?
Do you recommend a completion hysterectomy to patients who undergo primary radiation for endometrial cancer (presuming they are now a surgical candidate)?
If you recommend chemotherapy for early-stage uterine serous carcinoma, do you prefer 3 or 6 cycles?
